Understanding Biochemical Recurrence in Prostate Cancer

Biochemical recurrence (BCR), defined as a detectable or rising prostate-specific antigen (PSA) level after initial curative treatment like radical prostatectomy (surgical removal of the prostate gland), affects up to 30-50% of men within 10 years post-surgery. This early sign of returning cancer poses challenges for clinicians, as conventional imaging often fails to pinpoint the exact location or extent of disease at low PSA levels. Recent advancements are shifting paradigms, offering precise tools to guide salvage therapies and improve progression-free survival (PFS).

In the United States, where prostate cancer remains the most common non-skin cancer among men and the second leading cause of cancer death, such insights are vital. With an estimated 333,830 new cases projected for 2026, early detection and tailored intervention for recurrence could significantly enhance outcomes.

The Emergence of PSMA PET/CT Imaging

Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (PSMA PET/CT) is a highly sensitive imaging modality that targets PSMA, a protein overexpressed on prostate cancer cells. Unlike traditional CT or bone scans, PSMA PET/CT detects metastases even at low PSA levels (<0.5 ng/mL), revolutionizing staging for BCR. Approved by the FDA in 2020 for biochemical recurrence, it boasts detection rates exceeding 80% in high-risk cases.

This technology combines PET's molecular imaging with CT's anatomical detail, enabling precise localization of recurrent disease in the prostate bed, pelvic nodes, or distant sites. University research centers, such as UCLA's Jonsson Comprehensive Cancer Center, have been at the forefront of validating its clinical utility.

Breakthrough Findings from the JNCCN Study at UCLA

A pivotal study published in the February 2026 issue of the Journal of the National Comprehensive Cancer Network (JNCCN) analyzed five-year outcomes in 113 patients treated with PSMA PET/CT-guided salvage radiotherapy after radical prostatectomy. Led by John Nikitas, MD, at UCLA Jonsson Comprehensive Cancer Center, the retrospective analysis categorized patients based on scan findings: no visible disease (T0N0M0), local recurrence (TrN0M0), or nodal/distant metastases.

Key methodology involved staging all patients with PSMA PET/CT prior to salvage therapy, then tracking PFS under varied regimens: prostate bed radiotherapy alone, whole-pelvis radiotherapy (WPRT), or with androgen deprivation therapy (ADT).

Tailored Treatment Strategies Based on Scan Results

• T0N0M0 (No Visible Disease): Achieved the best PFS; WPRT offered no advantage over prostate bed radiotherapy alone, sparing patients broader radiation exposure.
• TrN0M0 (Local Visible Disease): WPRT significantly boosted PFS compared to prostate bed RT, targeting pelvic involvement effectively.
• Nodal or Distant Metastases: ADT combined with radiotherapy markedly improved PFS, underscoring systemic therapy's role.

These results demonstrate PSMA PET/CT's predictive power for long-term response, outperforming PSA levels alone.Read the full press release.

Why PSMA PET/CT Outshines PSA Monitoring

While PSA rise signals BCR, it lacks anatomical specificity. PSMA PET/CT provides actionable visuals, altering management in up to 60% of cases by revealing occult disease. Nikitas noted, "The information from these scans is strongly associated with long-term outcomes and frequently changes treatment recommendations." This precision reduces overtreatment risks like incontinence or bowel issues from unnecessary WPRT.

Commentary by E. Christopher Dee, MD, from Memorial Sloan Kettering Cancer Center, praises it as a shift to "anatomy-guided treatment," informing prospective trials.Explore JNCCN February 2026 issue.

Complementary Advances: Decipher Genomic Classifier

Another JNCCN-highlighted study from the VANDAAM trial (published January 2026) validated the Decipher genomic classifier for predicting early BCR in early-stage prostate cancer, particularly among African American men (AUC 0.984 post-adjustment). Led by Kosj Yamoah, MD, PhD, at Moffitt Cancer Center, it showed high-risk patients faced 16-21-fold higher BCR odds, aiding treatment intensification decisions.

Integrating genomic risk with imaging like PSMA PET/CT promises personalized care, addressing disparities where Black men have 1.7-2.2 times higher mortality.Urology Times coverage.

U.S. Prostate Cancer Landscape and Recurrence Burden

Prostate cancer's five-year survival nears 98% overall but drops to 38% for distant metastases. BCR precedes clinical progression in most cases, with 20-40% post-prostatectomy recurrence within five years. The American Cancer Society projects 626,140 cancer deaths in 2026, underscoring urgency.

• 1 in 8 men lifetime risk.
• 333,830 new U.S. cases in 2026.
• Higher incidence in African Americans.

University-led trials drive progress, benefiting from NIH funding and multidisciplinary teams.

Patient Impacts and Clinical Adoption

These insights empower shared decision-making: avoiding ADT's side effects (hot flashes, bone loss) when scans show no mets, or escalating for visible disease. Reduced toxicity enhances quality of life, with PFS gains translating to years of control. NCCN guidelines increasingly endorse PSMA PET/CT for BCR staging.

For patients, early salvage RT post-PSMA improves metastasis-free survival by 20-30% in trials.

University Research Driving Innovation

Institutions like UCLA and Moffitt exemplify higher education's role in oncology breakthroughs. Faculty researchers collaborate on imaging trials, genomic assays, and therapies, training the next generation. Explore research jobs or faculty positions in cancer studies at leading universities.

Such work not only advances patient care but fosters careers in precision medicine. Check academic CV tips for aspiring oncologists.

Future Directions and Ongoing Research

Prospective trials like EMBARK and PSMAfore build on these findings, testing PSMA-guided oligometastatic RT and novel ADTs. Integration with AI for scan interpretation and combination with immunotherapies holds promise. University centers are pivotal, securing grants for phase III studies.

Aspirants can find postdoc opportunities in prostate cancer research, contributing to global impacts.

Photo by Vitaly Gariev on Unsplash

Actionable Steps for Stakeholders

• Advocate for PSMA PET/CT access via insurance.
• Discuss genomic testing like Decipher pre-treatment.
• Support university funding for cancer research.
• Explore careers at university jobs in healthcare academia.

This JNCCN study marks a treatment breakthrough, personalizing care for recurring prostate cancer through academic innovation.